Warner chilcott, a subsidary of big pharma Actavis, has reached a settlement pharma deals agreement for Asacol tablets.
Big pharma, Warner Chilcott Company has entered into a pharma deals agreement with Zydus Pharmaceuticals USA and Cadila Healthcare to settle all outstanding patent litigation related to Zydus' generic version of Asacol HD (mesalamine) delayed-release tablets.
The pharma deals agreement remains subject to preparation and execution of definitive documentation.
Warner Chilcott Company will grant Zydus a royalty-bearing license to market its generic Asacol HD beginning on November 15, 2015.
Other terms of the settlement were not disclosed.
Actavis is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
Actavis markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries, and operates a global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories.
Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology.
Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
Read the full article at The economic Times
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Actavis (formerly Watson Pharmaceuticals)
Report: Partnering Deals and Alliances with Warner Chilcott
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity